Clinical Trials

91 results for Prostate Cancer


Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Other: Laboratory Biomarker Analysis, Radiation: Radiation Therapy
  • Study ID: NCT01833208
View Trial

18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.

  • Condition: Bone Metastases, Prostate Cancer
  • Intervention: Other: scintigraphy 99mTc-MDP-SPECT/CT., Other: 18F-NaF-PET/MR
  • Study ID: NCT02969564
View Trial

A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
  • Intervention: Drug: sodium selenite, Radiation: radiation therapy, Other: laboratory biomarker analysis, Other: pharmacological study, Other: questionnaire administration
  • Study ID: NCT02184533
View Trial

A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

  • Condition: Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, Recurrent Prostate Cancer
  • Intervention: Drug: onapristone, Drug: abiraterone
  • Study ID: NCT02049190
View Trial

A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Cabazitaxel, Drug: Enzalutamide, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Prednisone
  • Study ID: NCT02522715
View Trial

A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cance

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Biological: Glycosylated Recombinant Human Interleukin-7, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01881867
View Trial

A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Androgen Receptor Splice Variant Positive Castration-Resistant Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
  • Intervention: Drug: Enzalutamide, Other: Laboratory Biomarker Analysis, Drug: Niclosamide, Other: Pharmacological Study
  • Study ID: NCT02532114
View Trial

A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel
  • Study ID: NCT02985021
View Trial

STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherap

  • Condition: Prostate Cancer
  • Intervention: Drug: celecoxib, Drug: docetaxel, Drug: prednisolone, Drug: ADT, Drug: zoledronic acid, Drug: abiraterone, Procedure: orchiectomy, Radiation: Radiotherapy to the prostate, Drug: enzalutamide
  • Study ID: NCT00268476
View Trial

A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis
  • Study ID: NCT02598895
View Trial

A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: EC1169, Other: EC0652
  • Study ID: NCT02202447
View Trial

A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])

  • Condition: Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Sirolimus
  • Study ID: NCT02565901
View Trial

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

  • Condition: Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
  • Intervention: Radiation: Stereotactic Radiosurgery
  • Study ID: NCT02206334
View Trial

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Biological: Pembrolizumab, Biological: pTVG-HP Plasmid DNA Vaccine
  • Study ID: NCT02499835
View Trial

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

  • Condition: Castration Resistant Metastatic Prostate Cancer
  • Intervention: Drug: Testosterone cypionate, Drug: Enzalutamide, Drug: Testosterone Enanthate
  • Study ID: NCT02286921
View Trial

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castrate-resistant Prostate Cancer, mCRPC
  • Intervention: Drug: Sipuleucel-T, Radiation: Stereotactic Ablative Body Radiation
  • Study ID: NCT01818986
View Trial

A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: Apalutamide, Drug: Abiraterone acetate, Drug: Docetaxel, Drug: Prednisone
  • Study ID: NCT02913196
View Trial

A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)

  • Condition: Prostate Cancer
  • Intervention: Drug: Abiraterone acetate, Drug: Prednisone, Drug: ARN509, Drug: Ipilimumab, Drug: Cabazitaxel, Drug: Carboplatin
  • Study ID: NCT02703623
View Trial

A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: GT0918
  • Study ID: NCT02826772
View Trial

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry

  • Condition: Prostatic Neoplasms
  • Intervention: Other: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
  • Study ID: NCT02364531
View Trial

A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT02236637
View Trial

Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide

  • Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Selinexor
  • Study ID: NCT02215161
View Trial

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Metastatic Castrate-Resistant Prostate Cancer
  • Intervention: Drug: GS-5829, Drug: Enzalutamide
  • Study ID: NCT02607228
View Trial

TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)

  • Condition: Prostate Cancer
  • Study ID: NCT02512185
View Trial

Evaluation of Lymph Node Metastases in Men Undergoing Treatment With Sipuleucel-T for Metastatic Castrate-resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Sipuleucel-T, Procedure: Lymph Node Biopsy
  • Study ID: NCT02036918
View Trial

A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Radium-223, Biological: Sipuleucel-T
  • Study ID: NCT02463799
View Trial

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Condition: Prostatic Neoplasms
  • Intervention: Biological: Pembrolizumab 200 mg, Drug: Olaparib 400 mg, Drug: Docetaxel 75 mg/m^2, Drug: Prednisone 5 mg, Drug: Enzalutamide 160 mg, Other: Dexamethasone 8 mg
  • Study ID: NCT02861573
View Trial

PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

  • Condition: Prostate Cancer
  • Intervention: Drug: Enzalutamide, Drug: Abiraterone acetate, Drug: Sipuleucel-T
  • Study ID: NCT02353715
View Trial

A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Taxotere, Drug: Jevtana
  • Study ID: NCT02044354
View Trial

Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

  • Condition: Prostatic Neoplasms
  • Intervention: Other: 18F-Sodium Fluoride (NaF)
  • Study ID: NCT02677376
View Trial

A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Drug: ZEN003694
  • Study ID: NCT02705469
View Trial

A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Drug: ZEN003694, Drug: Enzalutamide
  • Study ID: NCT02711956
View Trial

A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: Niraparib
  • Study ID: NCT02854436
View Trial

Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer (mCRPC) to Identify Adaptive Mechanisms of Resistance

  • Condition: Prostate Cancer
  • Intervention: Procedure: Image-Guided Biopsies
  • Study ID: NCT02432001
View Trial

A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Drug: Abiraterone acetate, Drug: Enzalutamide
  • Study ID: NCT02125357
View Trial

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Rucaparib, Drug: Abiraterone acetate or Enzalutamide or Docetaxel
  • Study ID: NCT02975934
View Trial

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Rucaparib
  • Study ID: NCT02952534
View Trial

A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Dietary Supplement: Ascorbic Acid, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Placebo, Other: Quality-of-Life Assessment
  • Study ID: NCT02516670
View Trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or M

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Ipatasertib, Drug: Abiraterone, Drug: Placebo
  • Study ID: NCT03072238
View Trial

A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)

  • Condition: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
  • Intervention: Drug: enzalutamide, Drug: mifepristone, Other: laboratory biomarker analysis, Other: pharmacological study
  • Study ID: NCT02012296
View Trial

Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT03176381
View Trial

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer Metastatic
  • Intervention: Behavioral: High intensity aerobic and resistance training, Behavioral: Psychosocial support
  • Study ID: NCT02730338
View Trial

A Phase II Clinical Trial of Radium-223 Activity in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status

  • Condition: Prostate Cancer
  • Intervention: Drug: radium-223
  • Study ID: NCT03002220
View Trial

Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223

  • Condition: Prostatic Neoplasms, Castration-Resistant
  • Intervention: Drug: Xofigo (Radium-223 dichloride, BAY88-8223
  • Study ID: NCT02899104
View Trial

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Isovue-M 200
  • Study ID: NCT03071328
View Trial

Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223

  • Condition: Prostate Cancer Metastatic, Bone Metastases
  • Intervention: Drug: Radium-223 dichloride
  • Study ID: NCT03223597
View Trial

Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223

  • Condition: Prostate Cancer Metastatic, Bone Metastases
  • Intervention: Diagnostic Test: Blood tests
  • Study ID: NCT03223727
View Trial

A Randomized, Open Label, Phase IIB Trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated With Docetaxel

  • Condition: Prostate Cancer Metastatic, Metastasis
  • Intervention: Drug: Cabazitaxel, Drug: Abiraterone, Drug: Enzalutamide
  • Study ID: NCT03295565
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe